

NCCTG N08C1: Paclitaxel-Associated Acute Pain Syndrome Natural History Study

Fast Facts

Inclusion criteria

1. ≥ 18 years of age and be diagnosed with cancer.
2. Provide informed written consent.
3. Ability to complete questionnaire(s) by themselves or with assistance.
4. Planned use of paclitaxel (not nab-paclitaxel) at one of the following doses:
 - at least 175 mg/m² and planned at 2-4 week intervals (cycles being 2,3, or 4 weeks, respectively)
 - 70-90 mg/m² planned weekly (3 out of 4 weeks is OK)
5. Life expectancy > 6 months.
6. ECOG performance status 0 or 1.
7. Willingness to provide the biologic specimens as required by the protocol (see Sections 6.16, 14.0).
8. Mandatory research blood draw.

Exclusion criteria

1. Diagnosis (current or previous) of peripheral neuropathy (from diabetes or other causes).
2. Diagnosis (current or previous) of fibromyalgia.
3. Concurrent planned neutrophil colony stimulating factor therapy
4. Previous exposure to paclitaxel, or neurotoxic chemotherapy drugs including other taxanes, platinum agents, vinca alkaloids, or epothilones.